TriSalus Life SciencesTLSI +3.80%29 Net Current Asset Value is $0.16 as of Mar. 2026, which is 99% below its 10-year median of 29.57. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 569 Medical Devices & Instruments companies, TriSalus Life Sciences ranks worse than 88.58% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
TriSalus Life Sciences's net current asset value per share for the quarter that ended in Mar. 2026 was $0.16.
The historical rank and industry rank for TriSalus Life Sciences's Net Current Asset Value or its related term are showing as below:
TLSI'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 23 Med: 29.57 Max: 34.13
Current: 23.88
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of TriSalus Life Sciences was 34.13. The lowest was 23.00. And the median was 29.57.
TLSI's Price-to-Net-Current-Asset-Value is ranked worse than 88.58% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.99
vs TLSI: 23.88
TriSalus Life Sciences (NAS:TLSI) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
TriSalus Life Sciences Net Current Asset Value Related Terms
TriSalus Life Sciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Net Current Asset Value Chart
TLSI vs TMCI, LAB, SENS: Net Current Asset Value Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.16 mean?
TriSalus Life Sciences (TLSI) has a Net Current Asset Value of $0.16 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on TriSalus Life Sciences and its competitors. This is 99% below median its historical median of 29.57. Over the past decade, TriSalus Life Sciences' Net Current Asset Value has ranged from 23.00 to 34.13. According to the industry distribution chart, TriSalus Life Sciences ranks #504 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 88.6%.
Is TriSalus Life Sciences' Net Current Asset Value too high?
TriSalus Life Sciences' current Net Current Asset Value of $0.16 is 99% below median its 10-year median of 29.57. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 34.13. The Medical Devices & Instruments industry median Net Current Asset Value is 4.99. TriSalus Life Sciences' value of $0.16 is 96.8% below this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #504 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Net Current Asset Value compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #504 out of 569 companies for Net Current Asset Value. This places TriSalus Life Sciences in the lower half of its industry. The industry median Net Current Asset Value is 4.99. TriSalus Life Sciences' value of $0.16 is 96.8% below this benchmark. Historically, TriSalus Life Sciences' own Net Current Asset Value has ranged from 23.00 to 34.13 over the past decade. While the company's 10-year median is 29.57 vs. the industry median of 4.99, TriSalus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.99, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Net Current Asset Value of $0.16 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Net Current Asset Value is $0.16, which is 99% below median its own 10-year median of 29.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Net Current Asset Value is $0.16, which is 99% below median its 10-year median of 29.57 and 96.8% below the Medical Devices & Instruments industry median of 4.99. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Net Current Asset Value is $0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.
Key valuation signals for TLSI:
Net Current Asset Value: $0.16 (99% below median its 10-year median of 29.57)
GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
Industry Position: 96.8% below the Medical Devices & Instruments median (#504 of 569)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
